— Know what they know.
Not Investment Advice

DNA NYSE

Ginkgo Bioworks Holdings, Inc.
1W: +15.8% 1M: +75.5% 3M: +22.1% YTD: +41.8% 1Y: -15.9% 3Y: -82.7% 5Y: -97.5%
$12.35
-0.15 (-1.20%)
 
Weekly Expected Move ±16.1%
$8 $10 $12 $14 $16
NYSE · Healthcare · Biotechnology · Tech Score Buy · Power 64 · $806.8M mcap · 48M float · 2.82% daily turnover · Short 60% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NO EDGE
33.4 / 100
NoneWeakNarrowWide
Primary source: Network Effects  ·  ROIC: -44.0%  ·  5Y Avg: -117.6%
Cost Advantage
38
Intangibles
34
Switching Cost
30
Network Effect
43
Scale
22
The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. DNA has No discernible competitive edge (33.4/100). The business operates without significant structural advantages. The primary source of advantage is Network Effects. Negative ROIC of -44.0% indicates the company is currently destroying value, though this may reflect a growth investment phase.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets
$5
Low
$5
Avg Target
$5
High
Based on 1 analyst since Aug 5, 2026 earnings
Analyst Recommendations
Strong Buy: 0Buy: 4Hold: 3Sell: 4Strong Sell: 0
Rating Summary
ConsensusBuy
Avg Target$5.00
Analysts1
Price Target Change History
DateFirmAnalystOldNewChangeUpside @ CallStock@Call
2026-09-09 Oppenheimer — Initiated $5 — -28.0% $6.94
2025-08-25 BTIG — $7 $9 +2 -25.3% $12.05
2024-08-23 BTIG Mark Massaro $6 $7 +1 -15.7% $8.30
2022-11-28 Berenberg Bank — Initiated $6 — +226.1% $1.84
2022-08-16 BTIG — Initiated $6 — +60.4% $3.74
2022-06-16 Jefferies — Initiated $4 — +68.0% $2.59
2022-03-02 Cowen & Co. Steven Mah Initiated $12 — +210.9% $3.86

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

C-
Oct 02, 2026
DCF
1
ROE
1
ROA
1
D/E
1
P/E
1
P/B
4
The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. DNA receives an overall rating of C-. Strongest factors: P/B (4/5). Areas of concern: DCF (1/5), ROE (1/5), ROA (1/5), D/E (1/5), P/E (1/5).

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 19 Grade D
Profitability
20
Balance Sheet
77
Earnings Quality
49
Growth
35
Value
48
Momentum
40
Safety
0
Cash Flow
30
The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. DNA scores highest in Balance Sheet (77/100) and lowest in Safety (0/100). A grade of D flags significant fundamental concerns across multiple dimensions.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score
-8.79
Distress Zone
Piotroski F-Score
2/9
✗ ✗ ✗ ✓ ✗ ✗ ✗ ✓ ✗
Beneish M-Score
-3.44
Unlikely Manipulator
Ohlson O-Score
-5.13
Bankruptcy prob: 0.6%
Low Risk
Credit Rating
BB
Score: 41.3/100
Trend: Improving
Earnings Quality
—
OCF/NI: 0.59x
Accruals: -10.9%
The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. DNA scores -8.79, placing it in the Distress Zone (safe > 2.99, distress < 1.81). Historically, companies in this range face elevated bankruptcy risk. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. DNA scores 2/9, suggesting weak financial fundamentals — the company fails the majority of these accounting tests. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. DNA's score of -3.44 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. DNA's implied 0.6% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. DNA receives an estimated rating of BB (score: 41.3/100), with a improving trend.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E
-2.46x
PEG
-0.16x
P/S
7.21x
P/B
1.82x
P/FCF
-3.24x
P/OCF
—
EV/EBITDA
-3.43x
EV/Revenue
6.41x
EV/EBIT
-2.43x
EV/FCF
-3.77x
Earnings Yield
-47.26%
FCF Yield
-30.90%
Shareholder Yield
0.00%
Graham Number
—
Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. DNA currently has negative earnings — the P/E ratio is not meaningful.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden
0.984
NI / EBT
×
Interest Burden
1.002
EBT / EBIT
×
EBIT Margin
-2.637
EBIT / Rev
×
Asset Turnover
0.101
Rev / Assets
×
Equity Multiplier
2.150
Assets / Equity
=
ROE
-56.3%
The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. DNA's ROE of -56.3% is driven by Asset Turnover (0.101), indicating efficient use of assets to generate revenue. A tax burden ratio of 0.98 indicates minimal tax leakage — the company retains over 90% of pre-tax earnings.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate
0.00%
Fair P/E
8.50x
Intrinsic Value
—
Price/Value
—
Margin of Safety
—
Premium
—

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1372 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price
$12.34
Median 1Y
$4.14
5th Pctile
$0.85
95th Pctile
$20.08
Ann. Volatility
96.1%
Analyst Target
$5.00
25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

ExecutiveSalaryStockTotal
Mark Dmytruk Financial
ancial Officer
$450,000 $1,730,200 $2,195,450
Jason Kelly
Chief Executive Officer
$250,000 $— $262,500
Reshma Shetty &
resident & Chief Operating Officer
$250,000 $— $262,500

CEO Pay Ratio

1:1
CEO-to-Employee Pay Ratio
CEO Total Comp: $262,500
Avg Employee Cost (SGA/emp): $377,918
Employees: 485

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees
485
-41.9% YoY
Revenue / Employee
$350,835
Rev: $170,155,000
Profit / Employee
$-644,872
NI: $-312,763,000
SGA / Employee
$377,918
Avg labor cost proxy
R&D / Employee
$502,625
Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
ROE -10.0% -1.2% -1.5% -3.1% -2.4% -1.3% -1.1% -80.6% -63.8% -63.0% -65.8% -76.8% -63.5% -60.3% -57.8% -43.6% -50.0% -51.1% -55.8% -56.3% -56.29%
ROA -7.2% -84.8% -1.1% -2.3% -1.8% -91.4% -76.9% -57.2% -44.0% -42.5% -42.7% -45.8% -37.1% -36.0% -32.8% -22.1% -25.4% -25.0% -26.2% -26.2% -26.19%
ROIC 40.0% 64.8% -16.8% -11.4% -15.1% -2.0% -1.7% -1.3% -1.2% -1.7% -1.7% -1.2% -79.9% -71.1% -65.8% -43.6% -52.8% -49.5% -49.0% -44.0% -43.97%
ROCE -4.2% -87.4% -1.2% -1.6% -2.1% -89.8% -74.8% -56.5% -39.7% -59.5% -60.5% -56.8% -50.6% -43.1% -38.5% -31.5% -35.9% -30.1% -31.5% -32.2% -32.15%
Gross Margin 71.3% 55.2% 49.3% 55.8% 62.9% 69.3% 72.3% 77.5% 87.5% 81.0% 75.7% 75.6% 88.8% 78.1% 75.1% 70.1% 67.0% 1.2% 18.4% 91.5% 91.47%
Operating Margin -34.4% -11.3% -4.0% -4.5% -9.9% -2.4% -2.7% -2.3% -5.2% -5.1% -4.7% -4.0% -62.0% -2.4% -1.8% -1.3% -2.3% -2.1% -3.7% -2.9% -2.90%
Net Margin -1.3% -10.8% -3.5% -4.6% -10.1% -1.8% -2.5% -2.2% -5.5% -6.1% -4.4% -3.9% -63.3% -2.5% -1.9% -1.2% -2.1% -2.4% -4.2% -2.3% -2.32%
EBITDA Margin -23.7% -10.8% -4.0% -4.4% -9.7% -1.3% -2.4% -2.1% -3.1% -8.3% -4.4% -2.5% -39.4% -3.3% -1.4% -92.9% -1.7% -1.0% -3.3% -2.2% -2.20%
FCF Margin -57.4% -89.1% -60.2% -58.2% -65.3% -63.7% -1.0% -1.1% -1.3% -1.3% -1.5% -1.9% -1.8% -1.7% -1.5% -1.2% -1.0% -1.1% -1.3% -1.7% -1.70%
OCF Margin -33.1% -76.3% -51.5% -53.8% -59.3% -52.8% -82.8% -91.2% -1.1% -1.2% -1.4% -1.7% -1.5% -1.4% -1.2% -1.0% -91.8% -1.0% -1.2% -1.5% -1.52%
ROE 3Y Avg snapshot only -76.12%
ROE 5Y Avg snapshot only -1.01%
ROA 3Y Avg snapshot only -36.74%
ROIC 3Y Avg snapshot only -69.07%
ROIC Economic snapshot only -27.93%
Cash ROA snapshot only -17.20%
Cash ROIC snapshot only -32.60%
CROIC snapshot only -36.41%
NOPAT Margin snapshot only -2.05%
Pretax Margin snapshot only -2.64%
R&D / Revenue snapshot only 1.93%
SGA / Revenue snapshot only 1.43%
SBC / Revenue snapshot only 55.71%
Valuation
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
P/E Ratio -98.45 -7.25 -2.76 -1.30 -1.44 -1.49 -1.48 -2.94 -4.12 -3.75 -2.72 -0.77 -0.65 -0.93 -0.65 -1.96 -2.39 -1.47 -1.20 -2.12 -2.460
P/S Ratio 126.52 47.18 14.79 7.15 9.64 6.57 6.54 11.03 11.21 13.30 11.12 3.73 1.95 2.24 1.30 2.67 4.49 2.71 2.58 5.50 7.212
P/B Ratio 9.89 8.45 4.10 2.51 3.55 1.81 1.59 2.39 2.82 3.05 2.35 0.82 0.53 0.71 0.48 1.01 1.45 0.91 0.82 1.46 1.825
P/FCF -220.35 -52.97 -24.56 -12.30 -14.75 -10.31 -6.52 -9.74 -8.71 -9.94 -7.20 -1.98 -1.10 -1.33 -0.90 -2.25 -4.33 -2.37 -1.99 -3.24 -3.237
P/OCF — — — — — — — — — — — — — — — — — — — — —
EV/EBITDA -191.33 -6.71 -2.15 -0.87 -1.08 -1.09 -1.08 -2.54 -4.35 -3.21 -2.17 -0.54 -0.41 -0.86 -0.59 -1.95 -2.38 -2.11 -1.91 -3.43 -3.430
EV/Revenue 112.31 41.52 11.44 4.70 7.28 4.74 4.48 8.90 9.16 10.50 8.20 2.22 1.17 1.83 0.96 2.48 4.28 2.68 2.85 6.41 6.412
EV/EBIT -157.21 -6.62 -2.12 -0.86 -1.07 -1.07 -1.05 -2.41 -3.92 -2.96 -2.00 -0.49 -0.37 -0.76 -0.50 -1.60 -2.00 -1.48 -1.34 -2.43 -2.432
EV/FCF -195.60 -46.61 -19.00 -8.07 -11.15 -7.44 -4.47 -7.86 -7.12 -7.85 -5.31 -1.18 -0.66 -1.09 -0.66 -2.09 -4.13 -2.35 -2.19 -3.77 -3.773
Earnings Yield -1.0% -13.8% -36.2% -76.8% -69.4% -67.1% -67.5% -34.1% -24.3% -26.7% -36.8% -1.3% -1.5% -1.1% -1.5% -51.1% -41.9% -67.9% -83.4% -47.3% -47.26%
FCF Yield -0.5% -1.9% -4.1% -8.1% -6.8% -9.7% -15.3% -10.3% -11.5% -10.1% -13.9% -50.5% -90.9% -75.0% -1.1% -44.4% -23.1% -42.1% -50.3% -30.9% -30.90%
Price/Tangible Book snapshot only 1.637
EV/Gross Profit snapshot only 8.006
Shareholder Yield snapshot only 0.00%
Leverage & Solvency
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Current Ratio 20.05 12.79 10.71 11.84 11.71 8.38 6.92 7.49 6.78 6.11 5.34 4.71 5.79 5.62 4.88 5.41 4.39 4.92 5.15 4.57 4.572
Quick Ratio 20.01 12.76 10.66 11.78 11.67 8.36 6.91 7.49 6.78 6.11 5.34 4.71 5.79 5.62 4.88 5.41 4.39 4.92 5.15 4.57 4.572
Debt/Equity 0.01 0.02 0.02 0.03 0.04 0.25 0.25 0.27 0.32 0.22 0.24 0.54 0.56 0.65 0.67 0.70 0.76 0.82 0.93 0.96 0.962
Net Debt/Equity -1.11 -1.01 -0.93 -0.86 -0.87 -0.50 -0.50 -0.46 -0.52 -0.64 -0.62 -0.33 -0.21 -0.13 -0.13 -0.07 -0.07 -0.01 0.08 0.24 0.243
Debt/Assets 0.01 0.01 0.01 0.03 0.03 0.17 0.17 0.18 0.20 0.14 0.15 0.28 0.30 0.34 0.34 0.35 0.36 0.37 0.40 0.41 0.408
Debt/EBITDA -0.23 -0.01 -0.01 -0.02 -0.02 -0.21 -0.25 -0.36 -0.61 -0.29 -0.30 -0.59 -0.71 -0.97 -1.12 -1.46 -1.30 -1.93 -1.95 -1.93 -1.932
Net Debt/EBITDA 24.21 0.92 0.63 0.45 0.35 0.42 0.50 0.61 0.97 0.86 0.77 0.36 0.27 0.19 0.21 0.15 0.12 0.03 -0.18 -0.49 -0.487
Interest Coverage -76.86 -1008.19 -1140.78 -1850.31 -3779.76 -5352.49 — — — -9600.51 -9194.67 -8913.70 -7430.60 -5823.55 -4820.29 -3797.37 -4100.55 — — — —
Equity Multiplier 1.39 1.38 1.30 1.30 1.30 1.46 1.50 1.52 1.62 1.52 1.60 1.95 1.86 1.92 2.00 2.01 2.12 2.20 2.33 2.36 2.356
Cash Ratio snapshot only 4.154
Cash to Debt snapshot only 0.748
FCF to Debt snapshot only -0.470
Defensive Interval snapshot only 302.5 days
Efficiency & Turnover
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Asset Turnover 0.06 0.13 0.21 0.42 0.26 0.21 0.17 0.15 0.16 0.12 0.10 0.09 0.12 0.15 0.17 0.16 0.14 0.14 0.12 0.10 0.101
Inventory Turnover 11.34 31.53 22.01 44.04 51.55 52.86 25.19 22.45 26.18 24.49 32.55 186.48 1129.17 1849.22 — — — — — — —
Receivables Turnover 2.39 2.05 2.56 5.30 6.34 4.46 3.05 2.67 3.52 5.05 3.83 4.21 5.04 11.64 9.41 11.33 8.06 7.42 6.13 6.36 6.362
Payables Turnover 5.55 12.94 5.43 21.44 26.11 21.91 4.97 5.76 7.03 5.46 1.68 1.99 2.99 3.62 2.37 2.72 3.73 2.55 2.57 2.14 2.144
DSO 153 178 143 69 58 82 120 137 104 72 95 87 72 31 39 32 45 49 60 57 57.4 days
DIO 32 12 17 8 7 7 14 16 14 15 11 2 0 0 0 0 0 0 0 0 0.0 days
DPO 66 28 67 17 14 17 73 63 52 67 217 184 122 101 154 134 98 143 142 170 170.3 days
Cash Conversion Cycle 119 161 92 60 51 72 61 89 66 20 -111 -95 -49 -69 -115 -102 -52 -94 -83 -113 -112.9 days
Fixed Asset Turnover snapshot only 0.222
Cash Velocity snapshot only 0.370
Capital Intensity snapshot only 8.851
Growth (YoY)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue — — — 11.4% 3.4% 77.1% -11.0% -39.5% -40.3% -47.4% -46.5% -43.4% -30.8% -9.7% 13.8% 25.2% -17.1% -25.1% -40.5% -51.5% -51.54%
Net Income — — — -53.9% -21.7% -19.9% 26.7% 58.6% 75.7% 57.6% 50.4% 26.7% 24.1% 38.7% 44.7% 64.9% 47.9% 42.8% 35.5% 7.7% 7.74%
EPS — — — -42.8% -17.4% 1.1% 38.5% 65.3% 79.7% 60.2% 52.4% 31.1% 29.1% 41.6% 49.0% 67.1% 51.0% 46.5% 41.3% 18.5% 18.49%
FCF — — — -4.3% -4.0% -26.7% -48.3% -17.7% -17.5% -10.5% 17.6% 6.1% 4.4% -13.6% -7.2% 20.9% 51.7% 49.2% 46.9% 30.7% 30.66%
EBITDA — — — -54.3% -48.9% -24.8% 30.9% 60.9% 81.3% 60.6% 51.0% 33.1% 5.1% 41.0% 50.9% 61.6% 48.5% 55.4% 45.6% 28.6% 28.61%
Op. Income — — — -49.6% -41.3% -24.9% 28.4% 57.5% 74.9% 60.9% 52.8% 32.9% 31.1% 35.2% 43.1% 63.8% 45.1% 43.7% 36.8% 7.2% 7.22%
OCF Growth snapshot only 28.38%
Asset Growth snapshot only -19.57%
Equity Growth snapshot only -31.43%
Debt Growth snapshot only -5.76%
Shares Change snapshot only 13.19%
Growth (CAGR)
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue 3Y — — — — — — — — — — — 61.7% 21.6% -5.6% -18.5% -24.6% -30.1% -29.1% -28.7% -30.0% -29.99%
Revenue 5Y — — — — — — — — — — — — — — — — — — — 20.7% 20.72%
EPS 3Y — — — — — — — — — — — — — — — — — — — — —
EPS 5Y — — — — — — — — — — — — — — — — — — — — —
Net Income 3Y — — — — — — — — — — — — — — — — — — — — —
Net Income 5Y — — — — — — — — — — — — — — — — — — — — —
EBITDA 3Y — — — — — — — — — — — — — — — — — — — — —
EBITDA 5Y — — — — — — — — — — — — — — — — — — — — —
Gross Profit 3Y — — — — — — — — — — — 77.3% 29.7% 4.1% -8.0% -15.1% -23.0% -20.3% -24.8% -27.0% -27.03%
Gross Profit 5Y — — — — — — — — — — — — — — — — — — — 27.6% 27.56%
Op. Income 3Y — — — — — — — — — — — — — — — — — — — — —
Op. Income 5Y — — — — — — — — — — — — — — — — — — — — —
FCF 3Y — — — — — — — — — — — — — — — — — — — — —
FCF 5Y — — — — — — — — — — — — — — — — — — — — —
OCF 3Y — — — — — — — — — — — — — — — — — — — — —
OCF 5Y — — — — — — — — — — — — — — — — — — — — —
Assets 3Y — — — — — — — — — — — 40.4% -11.7% -12.7% -14.3% -14.9% -14.0% -23.9% -24.7% -24.4% -24.41%
Assets 5Y — — — — — — — — — — — — — — — — — — — 11.0% 11.02%
Equity 3Y — — — — — — — — — — — 33.7% -19.9% -21.9% -25.7% -26.4% -26.9% -33.6% -34.9% -34.6% -34.62%
Book Value 3Y — — — — — — — — — — — 14.5% -31.2% -29.5% -32.8% -33.4% -34.1% -37.4% -39.5% -39.9% -39.85%
Dividend 3Y — — — — — — — — — — — — — — — — — — — — —
Growth Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Revenue Stability — — — — — — — 0.32 0.23 0.01 0.90 0.02 0.00 0.16 0.81 0.76 0.89 0.82 0.78 0.04 0.045
Earnings Stability — — — — — — — 0.16 0.04 0.48 0.99 0.01 0.01 0.74 0.98 0.05 0.08 0.82 0.94 0.12 0.124
Margin Stability — — — — — — — 0.88 0.84 0.83 0.82 0.84 0.83 0.82 0.83 0.84 0.83 0.84 0.89 0.88 0.885
Rev. Growth Consistency 0.00 0.00 0.00 0.50 0.50 0.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.00 0.00 0.00 0.00 0.000
Earn. Growth Consistency 0.00 0.00 0.00 0.00 0.00 0.00 0.50 0.50 0.50 0.50 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.000
FCF Positive Streak 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Earnings Persistence — — — — — — — 0.50 0.50 0.50 0.50 0.89 0.90 0.85 0.82 0.50 0.81 0.83 0.86 0.97 0.969
Earnings Smoothness — — — — — — — — — — — — — — — — — — — — —
ROE Trend — — — — — — — 0.23 0.60 0.38 0.41 0.29 0.76 0.25 0.24 0.43 0.14 0.17 0.11 0.10 0.104
Gross Margin Trend — — — — — — — 0.12 0.14 0.20 0.20 0.17 0.17 0.13 0.09 0.04 -0.06 0.02 -0.06 0.00 0.001
FCF Margin Trend — — — — — — — -0.17 -0.67 -0.57 -0.74 -1.02 -0.81 -0.70 -0.18 0.32 0.50 0.37 0.20 -0.17 -0.166
Sustainable Growth Rate — — — — — — — — — — — — — — — — — — — — —
Internal Growth Rate — — — — — — — — — — — — — — — — — — — — —
Cash Flow Quality
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
OCF/Net Income 0.26 0.12 0.10 0.10 0.09 0.12 0.19 0.24 0.40 0.33 0.34 0.34 0.51 0.58 0.60 0.75 0.49 0.55 0.55 0.59 0.585
FCF/OCF 1.73 1.17 1.17 1.08 1.10 1.21 1.21 1.24 1.18 1.14 1.10 1.14 1.16 1.20 1.23 1.15 1.13 1.13 1.10 1.12 1.117
FCF/Net Income snapshot only 0.654
CapEx/Revenue 24.3% 12.8% 8.7% 4.4% 6.0% 10.9% 17.5% 22.1% 20.0% 16.2% 13.5% 22.6% 24.0% 27.5% 26.7% 15.8% 11.8% 13.5% 12.2% 17.8% 17.77%
CapEx/Depreciation snapshot only 0.232
Accruals Ratio -0.05 -0.75 -1.03 -2.07 -1.60 -0.80 -0.62 -0.43 -0.26 -0.28 -0.28 -0.30 -0.18 -0.15 -0.13 -0.05 -0.13 -0.11 -0.12 -0.11 -0.109
Sloan Accruals snapshot only -0.227
Cash Flow Adequacy snapshot only -8.565
Dividends & Buybacks
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Dividend Yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Dividend/Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Payout Ratio — — — — — — — — — — — — — — — — — — — — —
FCF Payout Ratio — — — — — — — — — — — — — — — — — — — — —
Total Payout Ratio — — — — — — — — — — — — — — — — — — — — —
Div. Increase Streak — — — — — — — — — — — — — — — — — — — — —
Chowder Number — — — — — — — — — — — — — — — — — — — — —
Buyback Yield 5.8% 7.0% 13.8% 23.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.00%
Net Buyback Yield 5.8% 7.0% 13.7% 23.1% -0.0% 0.0% 0.0% 0.0% 0.0% -0.0% -0.0% -0.1% -0.1% -0.0% -0.0% -0.0% -0.0% -1.8% -2.2% -1.3% -1.33%
Total Shareholder Return 5.8% 7.0% 13.7% 23.1% -0.0% 0.0% 0.0% 0.0% 0.0% -0.0% -0.0% -0.1% -0.1% -0.0% -0.0% -0.0% -0.0% -1.8% -2.2% -1.3% -1.33%
DuPont Factors
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Tax Burden (NI/EBT) 0.99 1.00 1.00 1.00 1.00 0.99 0.99 0.99 0.99 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.02 0.98 0.984
Interest Burden (EBT/EBIT) 1.82 1.04 1.00 1.01 0.99 1.00 1.04 1.03 1.18 1.00 1.00 1.08 0.94 1.00 1.04 0.89 0.88 1.02 1.00 1.00 1.002
EBIT Margin -0.71 -6.27 -5.40 -5.48 -6.79 -4.45 -4.27 -3.69 -2.34 -3.55 -4.10 -4.50 -3.17 -2.41 -1.91 -1.55 -2.13 -1.81 -2.12 -2.64 -2.637
Asset Turnover 0.06 0.13 0.21 0.42 0.26 0.21 0.17 0.15 0.16 0.12 0.10 0.09 0.12 0.15 0.17 0.16 0.14 0.14 0.12 0.10 0.101
Equity Multiplier 1.39 1.38 1.30 1.37 1.35 1.42 1.40 1.41 1.45 1.48 1.54 1.68 1.71 1.68 1.76 1.98 1.97 2.04 2.13 2.15 2.150
Per Share
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
EPS (Diluted TTM) $-4.71 $-45.87 $-58.40 $-73.10 $-86.58 $-45.37 $-35.91 $-25.34 $-17.59 $-18.05 $-17.08 $-17.47 $-12.46 $-10.54 $-8.70 $-5.75 $-6.10 $-5.64 $-5.11 $-4.68 $-4.68
Book Value/Share $46.89 $39.32 $39.34 $37.90 $35.19 $37.41 $33.55 $31.11 $25.69 $22.18 $19.75 $16.22 $15.27 $13.80 $11.94 $11.17 $10.06 $9.17 $7.44 $6.77 $6.77
Tangible Book/Share $45.70 $38.19 $38.29 $36.16 $33.31 $33.72 $30.06 $27.72 $22.44 $19.51 $17.24 $14.45 $13.75 $12.40 $10.67 $9.97 $8.96 $8.14 $6.62 $6.05 $6.05
Revenue/Share $3.66 $7.04 $10.90 $13.31 $12.95 $10.29 $8.14 $6.74 $6.46 $5.08 $4.17 $3.59 $4.17 $4.38 $4.38 $4.21 $3.25 $3.07 $2.37 $1.80 $1.80
FCF/Share $-2.10 $-6.28 $-6.56 $-7.74 $-8.46 $-6.56 $-8.16 $-7.64 $-8.31 $-6.80 $-6.45 $-6.75 $-7.41 $-7.36 $-6.37 $-5.00 $-3.36 $-3.50 $-3.08 $-3.06 $-3.06
OCF/Share $-1.21 $-5.37 $-5.61 $-7.16 $-7.68 $-5.43 $-6.74 $-6.15 $-7.02 $-5.97 $-5.88 $-5.94 $-6.41 $-6.16 $-5.20 $-4.33 $-2.98 $-3.08 $-2.79 $-2.74 $-2.74
Cash/Share $52.56 $40.48 $37.15 $33.99 $31.95 $28.35 $25.17 $22.88 $21.51 $19.08 $16.88 $14.22 $11.79 $10.82 $9.53 $8.63 $8.30 $7.62 $6.27 $4.87 $4.87
EBITDA/Share $-2.15 $-43.57 $-58.10 $-72.06 $-87.03 $-44.86 $-33.65 $-23.61 $-13.60 $-16.60 $-15.79 $-14.87 $-12.05 $-9.33 $-7.15 $-5.34 $-5.83 $-3.89 $-3.54 $-3.37 $-3.37
Debt/Share $0.49 $0.60 $0.68 $1.27 $1.47 $9.54 $8.43 $8.50 $8.28 $4.84 $4.69 $8.80 $8.53 $9.01 $8.01 $7.82 $7.60 $7.52 $6.90 $6.51 $6.51
Net Debt/Share $-52.06 $-39.88 $-36.47 $-32.72 $-30.48 $-18.81 $-16.74 $-14.38 $-13.24 $-14.25 $-12.19 $-5.41 $-3.27 $-1.81 $-1.52 $-0.82 $-0.70 $-0.10 $0.63 $1.64 $1.64
Academic Models
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Altman Z-Score — — — — — — — — — — — — — — — — — — — — -8.787
Altman Z-Prime snapshot only -19.824
Piotroski F-Score 2 2 2 4 2 3 3 3 3 4 4 2 3 2 3 4 2 3 3 2 2
Beneish M-Score — — — -6.34 -11.83 -6.05 -5.40 -4.83 -3.96 -5.49 -5.20 -5.21 -3.74 -3.07 -3.16 -2.58 -2.83 -3.26 -1.54 -3.44 -3.435
Ohlson O-Score snapshot only -5.132
ROIC (Greenblatt) snapshot only -38.57%
Net-Net WC snapshot only $-3.82
EVA snapshot only $-281869290.00
Credit
Metric Trend Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Current
Credit Rating snapshot only BB
Credit Score 59.46 61.07 61.98 32.24 32.92 31.86 43.02 42.89 43.28 31.97 32.18 30.16 29.96 29.56 29.63 29.73 29.73 40.88 41.42 41.28 41.285
Credit Grade snapshot only 12
Credit Trend snapshot only 11.556
Implied Spread (bps) snapshot only 475.000
Industry Credit Rank snapshot only 37
Sector Credit Rank snapshot only 34

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms